Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorambucil + polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
This combination regimen, referred to in clinical trial contexts as **CL-Pola-R-CHP**, is an investigational therapy being evaluated for the treatment of patients with double-hit or triple-hit diffuse large B-cell lymphoma (DLBCL). Although the input name specifies chlorambucil, the clinical trial context (NCT06034210) identifies the "CL" components as the HDAC inhibitor **chidamide** (tucidinostat) and the Bcl-2 inhibitor **lisaftoclax** (APG-2575). These are combined with **polatuzumab vedotin** (an anti-CD79b antibody-drug conjugate), **rituximab** (an anti-CD20 monoclonal antibody), and the **CHP** chemotherapy backbone (cyclophosphamide, doxorubicin, and prednisone). The regimen is specifically designed for elderly patients (aged 65 and above) who are ineligible for hematopoietic stem cell transplantation, aiming to improve outcomes in high-risk DLBCL by targeting multiple pathways including epigenetic regulation, apoptosis, and B-cell surface antigens.
- Other names
- Chidamide + Lisaftoclax + Polatuzumab Vedotin + Rituximab + Cyclophosphamide + Doxorubicin + PrednisoneTucidinostat + Lisaftoclax + Polatuzumab Vedotin + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone
02
Targets
CD20 (B-lymphocyte antigen CD20)TOP2A (DNA topoisomerase II)B-cell antigen receptor complex-associated protein beta chainGR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on chlorambucil + polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlorambucil + polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone.